Please assess the completion status of the following clinical trial:

Trial Title: A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antiretroviral therapy (ART)-experienced, Human Immunodeficiency Virus (HIV) -1 infected adults at least 18 years of age.~* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol).~* HIV-1 infection as documented by HIV-1 RNA \>400 copies/mL (c/mL) at Screening and with at least one consecutive HIV-1 RNA \>400 c/mL within the four months prior to Screening (unless the Screening HIV-1 RNA is \> 1000 c/mL where no additional plasma HIV-1 RNA assessment is needed).~* Have documented resistance (via Screening resistance test) to two or more different classes of antiretroviral agents. For subjects off ART for at least one month, if Screening resistance results provide a fully active agent and do not show two class resistance then historical resistance results from the subject's most recent resistance testing may be used, following consultation with the study virologist and /or medical monitor.~* Integrase inhibitor (INI)-naïve, defined as no prior exposure to any INI (e.g. RAL, elvitegravir, or GSK1349572).~* Able to provide written informed consent prior to Screening.~* French subjects: In France, subjects will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.~Exclusion Criteria:~* Screening resistance test result indicates no fully active antiviral agents are available for design of the background regimen.~* Subject-virus does not yield results using genotype/phenotype/tropism at Screening (assay data is essential for eligibility determination).~* Women who are breastfeeding.~* Any evidence of an active AIDS-defining condition (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ \<200c/mm3).~* Subjects with moderate to severe hepatic impairment as defined by Child-Pugh classification.~* Recent history (less than or equal to 3 months) of upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding.~* Anticipated need for hepatitis C therapy during the study.~* History or presence of allergy or intolerance to the study drugs or their components or drugs of their class.~* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma; other localized malignancies require agreement between the investigator and study medical monitor for inclusion of the subject.~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to Screening.~* Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulator.~* Treatment with any agent, other than licensed ART, which has documented activity against HIV-1 in vitro within 28 days of first dose of investigational product.~* Exposure to an experimental drug and/or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the experimental test agent - whichever is longer, prior to the first dose of IP.~* French subjects recruited at sites in France will be excluded if the subject has participated in any study using an investigational drug and/or vaccine within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer - prior to screening for the study or the subject plans to participate simultaneously in another clinical study.~* Any acute or verified Grade 4 laboratory abnormality.~* Alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN).~* ALT greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with \>35% direct bilirubin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1349572 + Raltegravir Placebo (Type: EXPERIMENTAL): Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
- Raltegravir + GSK1349572 Placebo (Type: ACTIVE_COMPARATOR): Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete